Zobrazeno 1 - 10
of 68
pro vyhledávání: '"fenómenos genéticos::variación genética::mutación [FENÓMENOS Y PROCESOS]"'
Autor:
Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Anas Gazzah, Ulrik Lassen, Alexander Stein, Patrick Y. Wen, Sascha Dietrich, Maja J. A. de Jonge, Jean-Yves Blay, Antoine Italiano, Kan Yonemori, Daniel C. Cho, Filip Y. F. L. de Vos, Philippe Moreau, Elena Elez Fernandez, Jan H. M. Schellens, Christoph C. Zielinski, Suman Redhu, Aislyn Boran, Vanessa Q. Passos, Palanichamy Ilankumaran, Yung-Jue Bang
Publikováno v:
Nature medicine, vol 29, iss 5
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
Scientia
Nature Medicine, 29(5), 1103-1112. Nature Publishing Group
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus trametinib (MEK inhibitor) in eight cohorts of patients with BRAFV600E-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c4ebaa45d1da62d0ac5f9e5a60659de
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
http://www.scopus.com/inward/record.url?scp=85152683237&partnerID=8YFLogxK
Autor:
Josep Tabernero, Eric Van Cutsem, Elena Garralda, David Tai, Filippo De Braud, Ravit Geva, Mark T J van Bussel, Katia Fiorella Dotti, Elena Elez, María J de Miguel, Kevin Litwiler, Danielle Murphy, Michelle Edwards, Van Karlyle Morris
Publikováno v:
Scientia
Background WNT974 is a small molecule inhibitor of Wnt signaling that specifically inhibits porcupine O-acyltransferase. This phase Ib dose-escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuxima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd5f044abd821df8649f422f22924992
https://doi.org/10.1093/oncolo/oyad007
https://doi.org/10.1093/oncolo/oyad007
Autor:
Zimmer, Kai, Kocher, Florian, Untergasser, Gerold, Kircher, Brigitte, Amann, Arno, Baca, Yasmine, Macarulla, Teresa, Tabernero, Josep
Publikováno v:
Scientia
Cancer genomics; Oncology Genómica del cáncer; Oncología Genòmica del càncer; Oncologia Polybromo-1 (PBRM1) loss of function mutations are present in a fraction of biliary tract cancers (BTCs). PBRM1, a subunit of the PBAF chromatin-remodeling c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::85bf64e2c4230b124ae9de2de62f059f
https://hdl.handle.net/11351/9989
https://hdl.handle.net/11351/9989
Autor:
Musri, Melina Mara, Venturi, Veronica, Ferrer, Xènia, Romero Cortadellas, Lídia, Hernandez Viedma, Gonzalo, Leoz Allegretti, María del Pilar, Beneitez Pastor, David, Ortuño Cabrero, Ana
Publikováno v:
Scientia
Hereditary anemias; Ineffective erythropoiesis; Rare blood disease Anèmies hereditàries; Eritropoesi ineficaç; Malaltia rara de la sang Anemias hereditarias; Eritropoyesis ineficaz; Enfermedad rara de la sangre Congenital dyserythropoietic anemia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::997a685a4a9336c0049fbb8a49df73fd
https://hdl.handle.net/11351/9938
https://hdl.handle.net/11351/9938
Autor:
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Amit Oza, Antonio González-Martín, Carol Aghajanian, William Bradley, Cara Mathews, Joyce Liu, John McNamara, Elizabeth S. Lowe, Mei-Lin Ah-See, Kathleen N. Moore
Publikováno v:
Scientia
Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Oza, A, González-martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E S, Ah-see, M & Moore, K N 2022, ' Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.22.01549
Disilvestro, P, Banerjee, S, Colombo, N, Scambia, G, Kim, B, Oaknin, A, Friedlander, M, Lisyanskaya, A, Floquet, A, Leary, A, Sonke, G S, Gourley, C, Oza, A, González-martín, A, Aghajanian, C, Bradley, W, Mathews, C, Liu, J, Mcnamara, J, Lowe, E S, Ah-see, M & Moore, K N 2022, ' Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial ', Journal of Clinical Oncology . https://doi.org/10.1200/JCO.22.01549
PURPOSE In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986 ), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c377cbc45ec231613ffe9f64fdb9a33
https://doi.org/10.1097/ogx.0000000000001120
https://doi.org/10.1097/ogx.0000000000001120
Autor:
Francisco Martínez-Jiménez, Ali Movasati, Sascha Remy Brunner, Luan Nguyen, Peter Priestley, Edwin Cuppen, Arne Van Hoeck
Publikováno v:
Scientia
Cancer genomics; DNA damage and repair; Metastasis Genòmica del càncer; Dany i reparació de l'ADN, Metàstasi Genómica del cáncer; Daño y reparación del ADN; Metástasis Metastatic cancer remains an almost inevitably lethal disease1,2,3. A bet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0103d691591ca8e1174fd7f6802874a
https://doi.org/10.1038/s41586-023-06054-z
https://doi.org/10.1038/s41586-023-06054-z
Publikováno v:
Scientia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Variants genòmiques; Catalunya Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Genomic variants; Catalonia Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Variantes genómicas; Cataluña Per saber la prevalenç
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::2d7538dcea3dafa5b04a41e6d27f17f2
https://hdl.handle.net/11351/9767
https://hdl.handle.net/11351/9767
Autor:
Francisco Martínez-Jiménez, Peter Priestley, Charles Shale, Jonathan Baber, Erik Rozemuller, Edwin Cuppen
Publikováno v:
Scientia
Immune surveillance escape is a hallmark of tumorigenesis1. Multiple studies have characterized the immune escape landscape across several untreated early-stage primary cancer types2–4. However, whether late-stage treated metastatic tumors present
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b846829cc80466a48ea0dfacac5f86f3
https://hdl.handle.net/11351/9954
https://hdl.handle.net/11351/9954
Autor:
Martinelli, Erika, Arnold, Dirk, Cervantes, Andrés, Stintzing, Sebastian, Van Cutsem, Eric, Tabernero Caturla, Josep
Publikováno v:
Scientia
Consensus; Metastatic colorectal cancer; Treatment Consens; Càncer colorectal metastàtic; Tractament Consenso; Cáncer colorrectal metastásico; Tratamiento Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic alt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::2050f58da1bbc03410c1f0a1080051ed
https://hdl.handle.net/11351/9258
https://hdl.handle.net/11351/9258
Autor:
Ciruela-Navas, Pilar, Cristino, Víctor, Martorell, Marta, Sabrià, Aurora, Velarde, José María, Mendioroz, Jacobo
Publikováno v:
Scientia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Variants genòmiques; Catalunya Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Genomic variants; Catalonia Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Variantes genómicas; Cataluña Per saber la prevalenç
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______3991::46fa30a3a4b50898ca53828265b92bde
https://hdl.handle.net/11351/9248
https://hdl.handle.net/11351/9248